|1||NCT02481297||Active, not recruiting||Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients||
||Other / Industry||
||8||All||18 Years and older (Adult, Senior)||NCT02481297||2014-0933
|June 23, 2015||June 2021||June 2021||June 25, 2015||June 22, 2017||
|2||NCT01592370||Active, not recruiting||An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, With or Without Pomalidomide and Dexamethasone, in Patients With Multiple Myeloma||
||375||All||18 Years and older (Adult, Senior)||NCT01592370||CA209-039||June 27, 2012||March 15, 2020||March 16, 2020||May 7, 2012||September 6, 2017||
† Study has passed its completion date and status has not been verified in more than two years.